Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis -- Ignore unavailable to you. Want to Upgrade?

To: Terror who wrote (130)	12/21/1997 9:39:00 PM
From: Valueman	Respond to of 296

Marcie: This is a fairly high entry point. Profit growth looks to be exceptional over the next few years, but p/e is high. My clients and I got in over 2 years ago, buying Ciba-Geigy before the merger. Our basis is in the high 30's. The most I have paid for new clients in recent memory is 70. At its current price, it may be undervalued based on future growth and vs. its peers, but it is not undervalued in the strict sense of the term. Swiss market is extremely volatile so NVTSY moves around quite a bit. I bet you can get it cheaper with a little patience. Good luck! Valueman P.S. You appear to be a long term investor by your previous posts--look into Loral(NYSE:LOR)here on the SI boards and the myriad of places that board will direct you and you will like it I am sure.

To: Terror who wrote (130)	12/22/1997 12:21:00 AM
From: Sonki	Respond to of 296

marcie, welcome to the thread. do yahoo research. chk out the foward pe on this stock w. others in the class. real value. compare to high pe u.s. drugs. i own mrk, wla, pfe, nvtsy.